arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

OMEROS CORP

OMER
$13.26 ▲ +0.12 (+0.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

OMEROS CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $842.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC 633.5%
FCF / Share $-1.83
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.73
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$111.81M
↑ +274.3%
Net Income Profit after all expenses
$-3.35M
↑ +97.9%
Operating Margin Operating profit as % of sales
-56.7%
↑ +84.9%
FCF / Share Free cash flow per share
$-1.83
↑ +28.6%
Long-Term Debt Long-term obligations
$87.90M
↓ -46.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
49
Financial Health
70
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters